Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a modest day gain of 1.84%, the stock’s technical indicators present a complex picture, with mixed signals across weekly and monthly timeframes, reflecting uncertainty in near-term price direction.

Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a modest day gain of 0.93%, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, Bollinger Bands, and moving averages, reflecting cautious investor sentiment in the Pharmaceuticals & Biotechnology sector.

Jagsonpal Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 27 Apr 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 03 May 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Jagsonpal Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, is currently exhibiting a complex technical profile with a shift from mildly bearish to sideways momentum. Despite a modest day gain of 1.20%, the stock’s technical indicators present a nuanced picture, reflecting both bullish and bearish signals across weekly and monthly timeframes.

Jagsonpal Pharmaceuticals Ltd., a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹1,359.00 crores, reported net profit of ₹8.76 crores for Q4 FY26, marking a robust 33.13% year-on-year growth from ₹6.58 crores in Q4 FY25. However, the quarter revealed concerning sequential trends as profits declined 20.00% from ₹10.95 crores in Q3 FY26, whilst revenues contracted 11.99% quarter-on-quarter to ₹64.20 crores. The stock traded at ₹207.00 on April 28, 2026, up 1.50% from the previous close, though it remains 31.41% below its 52-week high of ₹301.80.

Jagsonpal Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with recent indicators signalling a transition from sideways to mildly bearish trends. Despite a 2.26% gain on 28 Apr 2026, the stock’s technical parameters present a complex picture, reflecting both bullish and bearish signals across different timeframes.

Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 April 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical standing.

Jagsonpal Pharmaceuticals Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of bullish and bearish signals across key technical indicators. Despite a strong day change of 6.29%, the stock remains under a Sell mojo grade, underscoring cautious sentiment among investors in the Pharmaceuticals & Biotechnology sector.

Jagsonpal Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish indicators. Despite a marginal day decline of 0.05%, the stock’s technical parameters reveal a sideways trend, signalling a pause after recent volatility and prompting a reassessment of its near-term outlook.

Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a modest 1.14% gain on 15 Apr 2026, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, Bollinger Bands, and moving averages suggesting cautious investor sentiment in the Pharmaceuticals & Biotechnology sector.

Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a modest day gain of 0.58%, the stock’s technical indicators present a complex picture, with weekly signals showing mild bullishness contrasting with monthly bearish tendencies. This article analyses the recent technical parameter changes, key momentum indicators, and the implications for investors amid the broader Pharmaceuticals & Biotechnology sector.

Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 31 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its technical parameters, reflecting a complex interplay of bullish and bearish signals. Despite a 4.24% gain on the day, the stock’s overall momentum and technical indicators suggest a cautious outlook, with a recent downgrade from Hold to Sell by MarketsMOJO underscoring the evolving market sentiment.

Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 03 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.